Sallysamir Zahran
|
| Affiliation |
Egyptian Atomic Energy Authority |
| Country |
Egypt |
| Scopus ID |
56490517500 |
| Documents |
5 |
| Citations |
116 |
| h-index |
3 |
| Subject Area |
Drug Development |
| Event |
Global Scientist Day Awards |
Sallysamir Zahran
Institution: Egyptian Atomic Energy Authority
Country: Egypt
Sallysamir Zahran is associated with the Egyptian Atomic Energy Authority and contributes to scientific research in the interdisciplinary field of drug development. Research activities have focused on developing innovative pharmaceutical and biomedical solutions supported by experimental investigations and collaborative scientific approaches. Scholarly publications indexed in Scopus demonstrate sustained academic engagement and measurable citation impact within the international research community.[1]
Abstract
Drug development requires integration of pharmaceutical science, biomedical research, analytical methodologies, and translational innovation. Sallysamir Zahran’s scholarly work contributes to these objectives through research that supports improved therapeutic strategies and scientific understanding. The publication record indexed by Scopus reflects consistent scientific productivity, while citation metrics indicate that the research has been referenced by fellow investigators within related disciplines.[1]
Keywords
Drug Development, Pharmaceutical Sciences, Biomedical Research, Therapeutic Innovation, Drug Discovery, Translational Medicine, Experimental Pharmacology, Clinical Research, Medical Science, Scientific Publications
Introduction
Modern drug development combines chemistry, biology, pharmacology, toxicology, and clinical science to produce safe and effective therapeutic interventions. Researchers working within this multidisciplinary environment contribute to improving healthcare outcomes through systematic experimentation, validation, and scientific communication. Publications indexed by international databases such as Scopus provide evidence of research visibility and scholarly dissemination.[1]
Research Profile
Sallysamir Zahran is affiliated with the Egyptian Atomic Energy Authority and has established an academic profile within the field of drug development. According to the available Scopus author profile, the researcher has produced five indexed scholarly documents, accumulated 116 citations, and attained an h-index of 3. These indicators demonstrate measurable scientific engagement and continued participation in internationally indexed research activities.[1]
Research Contributions
The research contributions emphasize experimental investigations supporting pharmaceutical innovation and biomedical applications. Published studies contribute to scientific knowledge related to therapeutic development, laboratory evaluation, and evidence-based research methodologies. Collaborative investigations further strengthen interdisciplinary knowledge exchange while encouraging reproducibility and scientific transparency.[2]
Publications
Research publications indexed within Scopus demonstrate scholarly dissemination in drug development and associated biomedical sciences. These publications collectively contribute to scientific literature through experimental evidence and peer-reviewed communication. Representative research articles include publications with Digital Object Identifiers (DOIs), enabling persistent scholarly access.[2]
Research Impact
Citation-based indicators provide evidence that the published research has received attention from the broader scientific community. The available Scopus metrics indicate 116 citations across five indexed documents with an h-index of 3, reflecting measurable academic influence and continued relevance within drug development research.[1]
Award Suitability
Based on the available scholarly indicators, Sallysamir Zahran demonstrates characteristics commonly associated with academic recognition, including peer-reviewed publications, international indexing, measurable citation performance, and contributions to drug development research. The research portfolio aligns with the objectives of the Global Scientist Day Awards, which recognize scientific excellence, innovation, and continued advancement of research across diverse disciplines.[3]
Conclusion
Sallysamir Zahran has established a recognized research profile within the field of drug development through scholarly publications, citation impact, and international indexing. The documented research activities contribute to scientific knowledge while supporting continued innovation in pharmaceutical and biomedical sciences. The available academic record reflects meaningful participation in global research and represents a profile suitable for consideration within international scientific recognition programs.[1]
External Links
References
- Elsevier. (2026). Scopus Author Details: Sallysamir Zahran, Author ID 56490517500. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=56490517500
- Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer.
http://10.1016/j.bioorg.2025.109173
- Global Scientist Day Awards. (2026). Official Award Website.
https://scientistday.org/